Survival for patients surviving 6 months from the start of induction therapy
| . | Entire patient cohort, N = 207 . | Transplantation eligible, received auto-HCT, n = 86 . | Transplantation eligible, received allo-HCT, n = 12 . | Transplantation eligible, did not receive transplantation, n = 63 . | Transplantation ineligible because of comorbidities or age of >70 years, n = 46 . | P value . |
|---|---|---|---|---|---|---|
| Median PFS, mo (95% CI) | 38 (28-66) | 46 (36-86) | 26 (23-NR) | 24 (16-38) | 18 (8-NR) | <.01 |
| Median OS, mo (95% CI) | 68 (45-96) | 108 (75-NR) | 31 (16-NR) | 85 (40-108) | 21 (16-64) | <.01 |
| . | Entire patient cohort, N = 207 . | Transplantation eligible, received auto-HCT, n = 86 . | Transplantation eligible, received allo-HCT, n = 12 . | Transplantation eligible, did not receive transplantation, n = 63 . | Transplantation ineligible because of comorbidities or age of >70 years, n = 46 . | P value . |
|---|---|---|---|---|---|---|
| Median PFS, mo (95% CI) | 38 (28-66) | 46 (36-86) | 26 (23-NR) | 24 (16-38) | 18 (8-NR) | <.01 |
| Median OS, mo (95% CI) | 68 (45-96) | 108 (75-NR) | 31 (16-NR) | 85 (40-108) | 21 (16-64) | <.01 |
Auto-HCT, autologous hematopoietic cell transplantation; NR, not reached.